USA flag logo/image

An Official Website of the United States Government

Nonthrombogenic, Antiseptic Nitric Oxide Releasing Catheters

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43HL114148
Solicitation Year:
2012
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA11-096
Small Business Information
MC3, INC.
3526 W Liberty Rd Ste 100  ANN ARBOR, MI 48103-8872
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Nonthrombogenic, Antiseptic Nitric Oxide Releasing Catheters
Agency: HHS
Contract: 1R43HL114148-01
Award Amount: $195,577.00
 

Abstract:

DESCRIPTION (provided by applicant): This project will focus on the preparation and evaluation of nonthrombogenic, antibacterial nitric oxide (NO) releasing catheters. Phase 1 of this SBIR will: 1) develop unique NO secreting catheters (14-20 gauge); 2) test them in rabbit and sheep models to evaluate thrombogenicity and bacterial adherence; Phase 2 will scale up manufacturing and evaluate toxicity in preparation for human trials. The rationale for this research is to mimic the function of the endothelium.Low levels of NO released by the normal endothelium inhibit platelet adhesion and activation, thus preventing thrombus formation. Further, it has been shown that NO at low doses exhibits significant bactericidal activity. Hence, the preparation of catheters that secrete NO will solve two longstanding problems in the care of critically ill patients. The basic NO release polymer technology that employs novel diazeniumdiolate type NO donors has been developed in laboratories at the University of Michigan (U ofM) over the past 10 years. Successful applications of this technology have already included the development of anti-platelet coatings for extracorporeal circulation devices and the preparation more biocompatible implantable chemical sensors with improvedanalytical performance. Via collaboration with the research team at the U of M that has been working on this technology, MC3 now intends to develop and test catheters that release NO at controlled rates in order to prevent thrombosis and infection, two major problems associated with the use of catheters. PUBLIC HEALTH RELEVANCE: Clotting and infection is a major problem in intravascular (IV) catheters. Normal blood vessels secrete a chemical called nitric oxide which prevents these problems. This research will develop 14-20 gauge catheters which secrete nitric oxide, decreasing the risk of clotting and infection.

Principal Investigator:

Scott I. Merz
734-995-9089
merz@mc3corp.com

Business Contact:

Kathryn R. Osterholxer
734-995-9089
koster@mc3corp.com
Small Business Information at Submission:

MC3, INC.
3526 W LIBERTY RD, STE 100 ANN ARBOR, MI 48103-8802

EIN/Tax ID: 138266722
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No